Generation of a High-Affinity Nanobody Against CD147 for Tumor Targeting and Therapeutic Efficacy Through Conjugating Doxorubicin

Overview of attention for article published in Frontiers in immunology, May 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 53,353 followers.

Generation of a High-Affinity Nanobody Against CD147 for Tumor Targeting and Therapeutic Efficacy Through Conjugating Doxorubicin https://t.co/Fi3FnQ2nnl

23 May 2022

Reply Repost Favourite

Generation of a High-Affinity Nanobody Against CD147 for Tumor Targeting and Therapeutic Efficacy Through Conjugating Doxorubicin: CD147, a glycosylated transmembrane protein in the immunoglobulin superfamily, is overexpressed, #immunology… https://t.co/b

05 May 2022

Reply Repost Favourite

RT @FrontImmunol: New Research: Generation of a High-Affinity Nanobody Against CD147 for Tumor Targeting and Therapeutic Efficacy Through C…

04 May 2022

Reply Repost Favourite

New Research: Generation of a High-Affinity Nanobody Against CD147 for Tumor Targeting and Therapeutic Efficacy Through Conjugating Doxorubicin: CD147, a glycosylated transmembrane protein in the immunoglobulin superfamily, is overexpressed… https://t.co/U

04 May 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.